Prenetics' CEO and CFO Just Bought $1 Million of Stock — the Third Time in Nine Months. Here's What They're Buying

In the week after Prenetics reported second-quarter results, its CEO bought shares twice in four days as the stock ran: 7,500 at $18.31 on August 20, then another 17,181 at $21.23 on August 24. With the CFO's purchases, insiders put roughly $1.0 million into the open market. It is the third post-earnings round in nine months, after about $1.45 million in November and $1.3 million in February.

The first instinct is that insiders know something. Look at the size first. This is a company worth about $390 million. One million dollars is a quarter of one percent of it. And the stock had already nearly tripled from its 52-week low of $7.80, to $23 and change. Whatever the executives know, the market has already priced a large part of it. So what, exactly, are they buying — and does the price make sense? Answering that means getting past the insider trade to the machine behind it.

The machine is IM8. Eighteen months ago Prenetics was a Hong Kong health-sciences holding company with pieces of genetic testing, a cancer-detection venture, and a line of diagnostics. As recently as last fall it was telling investors it ran a "dual-engine" strategy of wellness and Bitcoin. Every one of those engines is now sold or shut. What is left is IM8, a twenty-month-old direct-to-consumer supplement brand co-founded with David Beckham, responsible for 97% of group revenue.

The second quarter is what drew the buyers in. Total revenue was $46.5 million, up 29% from the prior quarter and about 3.9x year over year. IM8 alone did $45.0 million at a 65% gross margin. The encouraging part is behavioral rather than promotional. Customer acquisition cost held roughly flat, edging from about $305 to $301, while acquisition spending nearly doubled to $35.7 million, then fell to about $239 in July. Customers are committing. Quarterly plans went from zero last October to 55% of July revenue, with an average first order of about $321. Active subscriptions sit near 140,000, and 87% of revenue is recurring. An independent card-spend firm, Indagari, finds IM8's customer retention at month twenty (14.2%) ahead of AG1, Thorne, and Grüns, at roughly double their price per transaction.

That is payment data, not press releases. It is the reason this is not the usual celebrity-supplement story, and it is the reason General Catalyst wrote a check. But the check is where the read gets careful.

On July 14, IM8 closed $1 billion of non-dilutive growth financing from General Catalyst's Customer Value Fund. The mechanics: General Catalyst funds up to 70% of IM8's monthly marketing spend, cohort by cohort, in return for a capped share of each cohort's collections — up to a 30% internal rate of return, or a return multiple ranging from 1.035x to 1.170x per cohort. No shares issued. It is a real, independent bet on the cohort economics, and the company is entitled to be proud of it.

Now the part the headline cannot tell you. The company's flagship claim this quarter is that "consolidated Adjusted Free Cash Flow turned positive" in July for the first time — the moment growth stops consuming cash. Read the definition. Adjusted free cash flow equals cash from operating activities plus net fundings under the General Catalyst facility. The facility went live July 14. The "inflection" landed the same month the lender started paying the marketing bills. That is disclosed plainly, and it is not a trick. But it means "the machine pays for its own growth" currently includes a lender's money, and the underlying operating business still burns cash: negative $27.9 million in the first half.

The before picture is shorter than it looks. In the first half of 2026 the company funded that burn, plus a $40 million buyback, by selling its entire Bitcoin stash for about $41 million and its remaining stake in the cancer-detection venture Insighta for about $69 million. The balance sheet is fine — roughly $109 million of cash and securities, no debt. The point is that the equity is now a pure bet on IM8's cohorts repaying, with nothing optional left in the portfolio to fall back on.

So what does the stock price? At $23, it trades around 2.7x trailing revenue, about 1.7x this year's guidance of $220–230 million, and roughly 1x the 2027 target of $400 million or more. Context for that multiple: in six months, strategics spent about $6.1 billion on three supplement brands — Danone on Huel at roughly $1.1 billion, Unilever on Grüns at about $1.2 billion, and P&G on Thorne at $3.8 billion, or 5.8x revenue. If IM8 really becomes a $400 million brand with a subscription base and clinical trials, the stock is not expensive.

The conditions are the problem, and they are all forward. The guidance implies a fourth quarter near $81 million, about 3x last year's Q4. The entire machine runs on essentially one product and two SKUs. And the cohorts responsible for 2027's growth are the youngest, largest, and most heavily financed ones — acquired at the highest marketing spend, financed 70% by General Catalyst. Their repayment is precisely the thing that cannot be verified yet. The company is honest about the weak spot; it says it does not build the plan on acquisition cost staying at $239. It also restated preliminary Q2 IM8 revenue down about 6%, from $47.8 million to $45.0 million, for sales taxes excluded under IFRS 15 — a reminder that headline run-rates are soft at the edges. There are also 2.36 million warrants exercisable at $18, with a call feature the company says it can trigger once shares trade at or above $21.60 for ten sessions; the stock is above that now. Called, they add roughly 14% more shares while bringing in about $42.5 million of cash.

So what is the insider buy worth? Three times in nine months, announced each time, small against the market cap and real in personal terms, sitting beside a $40 million company buyback. That is manufactured alignment, and it is a fact: management believes the machine. Believing is not pricing. The CEO's $1 million says he thinks IM8 is worth more at $21 than at $18. It says nothing about whether $23 is fair, or $40.

That question gets answered by cohort aging, which runs on a calendar, not a press release. Between now and the third-quarter report in November, there are four checkable things: whether adjusted free cash flow stays positive as General Catalyst fundings actually scale; whether acquisition cost holds near $240 as spending grows; whether the large 2026 cohorts pay back like the 2025 vintages did at the same age; and whether the fourth quarter is tracking to about $81 million. Watch those, not the Form 4s. The people who bought already know what they own. The test is whether the machine performs on the schedule they just priced.